Glaukos shares rose more than 7% in Thursday premarket trading after the company announced US Food and Drug Administration (FDA) approval for iDose TR (travoprost intracameral implant).
The iDose TR is a micro-invasive intraocular implant designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
The company said it is intended to improve the standard of care by addressing the ubiquitous patient non-compliance issues and chronic side effects associated with topical glaucoma medications.
“The FDA approval of iDose TR represents a significant milestone for Glaukos following an extensive pioneering journey since the inception of the original idea nearly 15 years ago,” Glaukos chairman and CEO Thomas Burns said in a statement.
“Today’s approval ushers in a new era of interventional glaucoma therapy by enabling a more proactive and reliable approach for patients in need.”
Ahead of the opening bell, Glaukos’ shares were up 7.6% at $60.42.